Ultrasound-guided botulinum toxin injection in patients with chronic plantar fasciitis: comparison of plantar fascia origin injection and the babcock method—a randomized controlled trial Authors: Arezou Darvishi, Fateme Hojjati, Amir hossein Mahdi kaghazi, Ali Nazari Nodoushan, Amirhossein Hajialigol, Seyed Ahmad Raeissadat Published: 2026 ABSTRACT AbstractAimsTo compare the effectiveness and safety of ultrasound-guided botulinum toxin injection at the plantar fascia origin with the two-point Babcock technique in patients with chronic plantar fasciitis.Materials and MethodsThis randomized clinical trial compared two ultrasound-guided botulinum toxin injection techniques. Pain intensity, foot function, pressure-pain threshold, and ultrasonographic plantar fascia thickness were assessed at baseline and at 6 and 24 weeks. Between-group comparisons were adjusted for baseline values, and treatment effects were reported with 95% confidence intervals.ResultsSixty participants were randomized, and 53 completed follow-up. At 24 weeks, the Babcock group showed a greater improvement in Foot Function Index–Revised scores than the plantar-fascia-origin group (adjusted mean difference, −14.18; 95% CI, −20.70 to −7.66; p < 0.001). Pressure-pain threshold was also higher in the Babcock group at 6 weeks (adjusted mean difference, 4.86; 95% CI, 2.65–7.08; p < 0.001) and 24 weeks (7.97; 95% CI, 5.23–10.72; p < 0.001). No significant between-group differences were found for pain intensity at 6 weeks (p = 0.191) or 24 weeks (p = 0.529). No serious intervention-related adverse events occurred.ConclusionsBoth techniques were associated with improvement. The Babcock technique may provide additional functional and pressure-pain benefits, although larger multicenter trials are needed.Clinical trial registration: www.irct.ir; registration number: IRCT20130523013442N33 Registration date: 2023-09-17, https://irct.ir/trial/72584 Introduction Plantar fasciitis is the most common cause of inferior heel pain in adults and is frequently encountered in outpatient musculoskeletal practice [1,2]. Heel pain affects approximately 4–7% of the general population, and plantar fasciitis accounts for nearly 80% of these cases [2,3]. The condition may cause considerable pain, functional limitation, reduced productivity, and increased healthcare utilization [4,5]. The plantar fascia is a thick fibrous aponeurosis originating from the medial calcaneal tubercle and contributes to maintenance of the longitudinal arch and absorption of mechanical stress during gait [1,6]. Although historically regarded as an inflammatory disorder, plantar fasciitis is now understood primarily as a degenerative condition characterized by repetitive microtrauma and collagen disorganization. Tightness of the gastrocnemius–soleus complex and dysfunction of the intrinsic foot muscles may increase mechanical stress on the plantar fascia and contribute to persistent symptoms [7,8]. Diagnosis is primarily clinical, although ultrasonography and magnetic resonance imaging may be used to confirm plantar fascia thickening or exclude alternative causes of heel pain [9,10]. Initial management typically includes activity modification, appropriate footwear, orthoses, stretching exercises, physical modalities, and nonsteroidal anti-inflammatory drugs [6,10]. Most patients respond to conservative treatment, but persistent or refractory cases may require injectable interventions [11–14]. Corticosteroid injection has traditionally been used for refractory plantar fasciitis, but its benefits may be temporary and repeated injections are associated with potential complications, including plantar fascia rupture and fat-pad atrophy [14,15]. Several alternative injectable therapies have therefore been investigated, including platelet-rich plasma, autologous blood, ozone, dextrose prolotherapy, hyaluronic acid, and autologous conditioned serum [16–20]. Botulinum toxin type A has emerged as another potential treatment for chronic plantar fasciitis because of its analgesic and muscle-relaxing effects [21–24]. It inhibits acetylcholine release at the neuromuscular junction and may also reduce the release of pain-related neuropeptides, including substance P, glutamate, and calcitonin gene-related peptide [25]. Clinical studies have reported improvements in pain and function after botulinum toxin injection, but the optimal injection site and technique remain uncertain [26,27]. Traditional injection approaches commonly target the plantar fascia origin at the calcaneus, where pain and pathological thickening are often most prominent [28]. Previous studies have reported beneficial effects of botulinum toxin type A in chronic plantar fasciitis using different injection sites and techniques. Babcock et al. administered the total dose across two plantar injection sites and reported improvements in pain and function compared with placebo [26]. Other studies have targeted the plantar fascia under ultrasound guidance or injected intrinsic foot muscles, suggesting that several anatomical targets may provide clinical benefit [8,29,30]. However, the considerable variation in injection sites, doses, and techniques limits direct comparison across studies, and current evidence does not establish that a two-point injection is superior to a single-point plantar fascia injection. Therefore, this randomized clinical trial aimed to compare the effectiveness and safety of a single-point ultrasound-guided botulinum toxin injection at the plantar fascia origin with the two-point Babcock technique in patients with chronic plantar fasciitis. We hypothesized that clinical outcomes would differ between the two injection techniques, particularly regarding functional improvement measured using the FFI-R, without prespecifying the superiority of either approach. Methodology Study design This randomized, participant- and assessor-blinded clinical trial was conducted at the Physical Medicine and rehabilitation Clinic of Shahid Modarres Hospital and Modava Clinic, affiliated with Shahid Beheshti University of Medical Sciences, Tehran, Iran. The study adhered to the principles of the Declaration of Helsinki and followed CONSORT reporting guidelines. Ethical approval for the study was obtained from the institutional ethics committee under the code IR.SBMU.MSP.REC.1403.099, and the study was registered in the Iranian Registry of Clinical Trials with the identifier IRCT20130523013442N33. Sample size The primary outcome was functional improvement measured using the Foot Function Index–Revised (FFI-R), with the principal endpoint defined as the between-group difference in FFI-R score at 24 weeks after injection. Secondary outcomes included pain intensity measured using the Visual Analog Scale, pain pressure threshold, ultrasonographic plantar fascia thickness, patient satisfaction, and adverse events. All clinical outcomes were assessed at baseline and at 6 and 24 weeks after the intervention, except patient satisfaction, which was assessed at 24 weeks. The sample size was calculated based on the primary outcome of functional improvement measured by the FFI-R. Based on effect estimates and variability reported in previous studies by Díaz-Llopis et al., Ahadi et al., and Huang et al. evaluating botulinum toxin treatment for plantar fasciitis [14,29,30], we assumed a clinically relevant between-group difference of 12 points and a standard deviation of 15 points. With a two-sided α of 0.05 and 80% power, 25 participants were required per group. Allowing for an anticipated dropout rate of approximately 15–20%, the target sample size was increased to 30 participants per group, resulting in a total planned enrollment of 60 participants. Inclusion criteria Patients aged between 30 and 60 years with a diagnosis of unilateral plantar fasciitis, persisting for at least three months and had not responded to conservative treatments, including activity modification, nonsteroidal anti-inflammatory drugs, physical modalities, and exercise therapy. Exclusion criteria Bilateral plantar fasciitis, uncontrolled diabetes mellitus, body mass index (BMI) greater than 33, radicular low back pain with lower limb involvement, history of previous surgery for plantar fasciitis, any injection therapy for plantar fasciitis within the previous three months, systemic inflammatory diseases (rheumatoid arthritis or seronegative arthropathies), vascular insufficiency, neuropathic pain, clinical signs of tarsal tunnel syndrome, marked ankle joint effusion, retrocalcaneal bursitis, Achilles tendinopathy, previous calcaneal fractures, bone cysts or tumors at the heel, severe foot deformities, marked muscle atrophy, local infection, use of anticoagulant medications, neuromuscular junction disorders, and known hypersensitivity to botulinum toxin. Eligible patients were evaluated at their initial visit. The assessment included a detailed medical history with demographic data, physical examination and clinical characteristics. All participants were informed about the study objectives, procedures, and potential risks, and written informed consent was obtained prior to enrollment. Randomization and blinding Our randomized, parallel-group, participant- and assessor-blinded clinical trial compared two ultrasound-guided botulinum toxin injection techniques in patients with chronic plantar fasciitis. Participants were unaware of their assigned injection technique, and all follow-up outcomes were assessed by an independent physiatrist who was blinded to group allocation. Because of the procedural differences between the interventions, the clinician performing the injections could not be blinded. However, the injector was not involved in follow-up assessments, data entry, or statistical analysis.Participants were randomly assigned to the single-point injection group or the two-point Babcock injection group using permuted block randomization with a fixed block size of six and a 1:1 allocation ratio. No stratification factors were used. The random allocation sequence was generated using Random Allocation Software. Group assignments were coded as A for botulinum toxin injection at the plantar fascia origin and B for botulinum toxin injection using the Babcock technique. Each assignment was recorded on a card and placed sequentially in a numbered, sealed, opaque envelope. The envelopes were stored in numerical order and opened consecutively according to each participant’s order of enrollment, after eligibility confirmation and completion of the baseline assessment. This procedure ensured allocation concealment until assignment to the intervention group. Intervention All injections were performed under strict aseptic conditions by an experienced physiatrist. Botulinum toxin type A (500 units) was reconstituted with 5 mL of normal saline, resulting in a standardized dilution. From this preparation, a total volume of 1.5 mL was allocated for each patient. The solution was stored and handled in accordance with cold chain requirements prior to administration. Patients were positioned prone, with the knee flexed at 90 degrees and the ankle maintained in a neutral position. Before injection, a standardized sonographic examination was performed using a high-frequency linear transducer. Both longitudinal and transverse scans were obtained to assess the thickness, echotexture, and continuity of the plantar fascia, the adjacent intrinsic muscles of the foot, and the cortical surface of the calcaneus. The medial calcaneal tubercle and plantar fascia origin were identified before needle insertion. The transducer was then positioned according to the planned injection site, and the needle was advanced under continuous ultrasound guidance using either an in-plane or out-of-plane approach, as specified for each intervention group [31]. In the first group, a high-frequency linear ultrasound probe (6–12 MHz) was placed longitudinally over the heel at the origin of the plantar fascia. Under ultrasound guidance, a 23-gauge needle was advanced using an in-plane technique toward the insertion of the plantar fascia at the calcaneus (Figure 1). With a single needle entry, 1 mL of 2% lidocaine was first administered, followed by the injection of 1.5 mL (equivalent to 150 units) of botulinum toxin at the same site. In the second group, a total volume of 1.5 mL (150 units) of botulinum toxin was divided into two syringes (0.9 mL and 0.6 mL) and administered using the two-point Babcock technique. For the first injection, the procedure was performed similarly to the single-point group at the origin of the plantar fascia under ultrasound guidance. Using an in-plane approach and a single needle entry, 0.5 mL of 2% lidocaine was injected, followed by 0.9 mL (90 units) of botulinum toxin at the calcaneal insertion of the plantar fascia. For the second injection, the ultrasound probe was positioned longitudinally along the medial border of the plantar fascia, approximately 2 cm distal to the medial calcaneal tuberosity in the medial plantar arch. Using an out-of-plane approach from the medial side, a 23-gauge needle was advanced at an angle of approximately 45° into the interfascial plane between the plantar fascia and the flexor digitorum brevis muscle. First, 0.5 mL of 2% lidocaine was injected. Without withdrawing the needle, 0.6 mL of botulinum toxin type A, equivalent to 60 units, was then administered into the same plane. (Figure 2). Ultrasound-guided single-point injection at the plantar fascia origin. The clinical photograph shows the longitudinal placement of the ultrasound probe and the in-plane needle approach toward the plantar fascia insertion at the medial calcaneal tubercle. The corresponding ultrasound image identifies the plantar fascia, calcaneus, needle trajectory, and injection site. PF, plantar fascia; Cal, calcaneus; arrow, plantar fascia; white arrow, needle; arrowhead, needle tip. Second injection site of the two-point Babcock technique. The ultrasound probe was positioned longitudinally along the medial border of the plantar fascia, approximately 2 cm distal to the medial calcaneal tuberosity in the medial plantar arch. A 23-gauge needle was introduced from the medial side at an angle of approximately 45° using an out-of-plane approach. The injection was administered into the interfascial plane between the plantar fascia and the flexor digitorum brevis muscle. The corresponding ultrasound image identifies the plantar fascia, calcaneus, needle trajectory, and injection site. PF, plantar fascia; Cal, calcaneus; black arrow, calcaneus; star, flexor digitorum brevis muscle. Following the procedure, patients were instructed to remain seated and avoid movement of the affected foot for approximately 10 minutes. They received both written and verbal instructions regarding stretching exercises and were provided with contact information for follow-up communication. Patients were advised to limit physical activity for three days and to use acetaminophen if pain occurred. In addition, they were systematically monitored for potential post-injection adverse events, including local inflammation, swelling, increased pain, injection site infection, and lower limb muscle weakness. To ensure patient safety, a 24 hour contact number was provided for reporting complications, with the principal investigator available for consultation. Data collection and management Demographic and clinical data including age, gender, BMI and duration of symptoms were recorded in predesigned checklists. Clinical outcomes were assessed at baseline and at 6 and 24 weeks post-intervention using validated tools to measure pain, function, mechanical sensitivity, and structural changes. Pain intensity was evaluated using the VAS, in which patients rated their pain on a scale from 0 (no pain) to 10 (the worst pain imaginable). Functional impairment was assessed using the Foot Function Index–Revised (FFI-R), a validated and reliable subjective questionnaire consisting of 17 items. Each item is scored on a scale from 0 to 10, with lower total scores indicating better functional status and less disability. Pain pressure threshold (PPT) was measured using an analog algometer equipped with a rubber-tipped probe with a surface area of 1 cm2. The device was applied perpendicularly to the medial tubercle of the calcaneus, and pressure was gradually increased until the patient first reported pain. The minimum pressure required to elicit pain was recorded. This measurement was repeated three times at 30-second intervals, and the mean value was used for analysis. Higher PPT values indicated reduced pain sensitivity.Plantar fascia thickness was assessed using ultrasonography thickness values (USV). Patient satisfaction with the treatment outcome was assessed at the 24-week follow-up using a single-item five-point Likert scale. Participants rated their overall satisfaction as 1: very unsatisfied, 2: unsatisfied, 3: neutral, 4: satisfied, or 5: very satisfied. Satisfaction responses were summarized as frequencies and percentages and compared between the two intervention groups using an appropriate categorical test. Patients were positioned prone with the ankle in a neutral position. A high-frequency linear probe was placed longitudinally over the medial calcaneal tuberosity, and the maximum thickness of the plantar fascia at its origin was measured. Plantar fascia thickness, as measured by ultrasonography, correlates with symptom severity and aids in the diagnosis of plantar fasciitis. A threshold of >4 mm has been reported as abnormal in several studies. Notably, a decrease in thickness may accompany clinical improvement [32,33]. (Figure 3) To support clinical interpretation, published minimal important difference estimates were considered where available. For plantar heel pain, reported minimal important differences on a 0–10 VAS are approximately 0.85 points for average pain and 1.92 points for first-step pain [34]. A minimal important difference of approximately 6.5 points has been reported for the original Foot Function Index [35]; however, a validated threshold has not been established specifically for the 17-item Foot Function Index–Revised used in the present study. Furthermore, no established minimal clinically important differences are currently available for pain pressure threshold or ultrasonographic plantar fascia thickness in plantar fasciitis. Accordingly, these outcomes were interpreted using absolute changes, between-group differences, effect sizes, and 95% confidence intervals. Ultrasonographic measurement of plantar fascia thickness. The clinical photograph shows longitudinal probe placement over the medial calcaneal tuberosity. On the ultrasound image, plantar fascia thickness was measured at its origin using a perpendicular measurement from the superficial to the deep fascial border. The red line indicates the measurement site. After the injection, participants in both groups received the same standardized home-based exercise program and were instructed to perform the prescribed exercises regularly throughout the follow-up period. The exercise technique and recommended frequency were explained verbally and demonstrated by the treating clinician. Adherence was reviewed at the 6- and 24-week follow-up visits through participant self-report regarding whether the exercises had been performed as instructed. However, adherence was not documented using a daily exercise diary, attendance log, digital monitoring system, or predefined quantitative adherence threshold. Statistical analysis All statistical analyses were performed using SPSS software (version 26.0.0.0; IBM Corp., Armonk, NY, USA). Data were first assessed for normality using the Shapiro–Wilk test. Continuous variables were presented as mean ± standard deviation (SD), while categorical variables were expressed as frequencies and percentages. Baseline characteristics between the two groups were compared using independent samples t-test for continuous variables and chi-square test (or Fisher’s exact test when appropriate) for categorical variables. Within-group changes over time (baseline, 6 weeks, and 24 weeks) were analyzed using repeated measures analysis of variance (RM-ANOVA). For the repeated-measures analyses, sphericity was evaluated using Mauchly’s test. When Mauchly’s test was significant, Greenhouse–Geisser-corrected degrees of freedom and p values were reported. Homogeneity of variance across treatment groups was assessed using Levene’s test. Repeated-measures ANOVA was conducted as a complete-case sensitivity analysis because participants with incomplete observations at any assessment point were excluded from this model. When significant time effects were observed, post hoc pairwise comparisons with Bonferroni correction were applied. Between-group comparisons at each follow-up time point were performed using independent samples t-tests. For non-normally distributed variables, corresponding non-parametric tests (Mann–Whitney U test and Friedman test) were used as appropriate. All statistical tests were two-tailed, and a p value of less than 0.05 was considered statistically significant. Effect sizes (Cohen’s d) were calculated to estimate the magnitude of differences between groups. Missing data were handled using a per-protocol analysis, including only participants who completed the follow-up assessments. The primary analyses followed the intention-to-treat principle and included all 60 randomized participants in their originally assigned groups. Missing follow-up outcomes were addressed using multiple imputation under the missing-at-random assumption. Fifty imputed datasets were generated using an imputation model that included treatment allocation, age, sex, body mass index, symptom duration, and baseline and available follow-up measurements for all continuous outcomes. Estimates were combined across imputed datasets according to Rubin’s rules. The primary endpoint, the FFI-R score at 24 weeks, was compared between groups using analysis of covariance, with treatment group as a fixed factor and baseline FFI-R score as a covariate. Corresponding baseline-adjusted models were used for the 6-week FFI-R score and the secondary continuous outcomes. Adjusted means, adjusted between-group mean differences, 95% confidence intervals, and two-sided p values were reported. Complete-case analyses were additionally conducted as sensitivity analyses. Effect sizes were reported alongside inferential estimates. For baseline-adjusted ANCOVA models, partial eta squared (partial η2) was reported for the treatment-group effect, with values of approximately 0.01, 0.06, and 0.14 interpreted as small, moderate, and large, respectively. For unadjusted between-group comparisons, Cohen’s d was calculated using the pooled standard deviation, with absolute values of approximately 0.20, 0.50, and 0.80 interpreted as small, moderate, and large effects, respectively. Results Participant flow and baseline characteristics A total of 60 participants were randomized, with 30 assigned to each intervention group. By the 24-week follow-up, seven participants had incomplete outcome data, including five in the plantar-fascia-origin group and two in the Babcock group. In the plantar-fascia-origin group, three participants were lost to follow-up because they could not be contacted and two withdrew for personal reasons. In the Babcock group, two participants were lost to follow-up because they could not be contacted. No participant discontinued treatment because of a serious intervention-related adverse event. All 60 randomized participants were included in the intention-to-treat analysis, whereas the complete-case sensitivity analysis included the 53 participants with complete measurements at all assessment points. Complete-case analyses were performed as sensitivity analyses to assess the robustness of the findings obtained from the primary multiple-imputation intention-to-treat analysis. The overall pattern of results was generally consistent between the two approaches, particularly for the 24-week FFI-R and PPT outcomes. Outcomes showing inconsistency between the imputed and complete-case analyses were interpreted cautiously. The progression of participants through enrollment, randomization, allocation, follow-up, and analysis is presented in the CONSORT flow diagram (Figure 4). Baseline demographic and clinical characteristics were comparable between the two groups, with no statistically significant differences in age, sex distribution, BMI, duration of symptoms, or baseline outcome measures including VAS, FFI-R, PPT, and plantar fascia thickness (USV) (p > 0.05) (Table 1). CONSORT flow diagram of participant enrollment, allocation, follow-up, and analysis. Sixty participants were randomized equally to the plantar-fascia-origin and Babcock groups. At 24 weeks, complete outcome data were available for 25 participants in the plantar-fascia-origin group and 28 in the Babcock group. CONSORT, Consolidated Standards of Reporting Trials. Table 1.Baseline demographic and clinical characteristics of the participants.VariableSingle-point group (N = 25)Two-point group (N = 28)p valueAge, years49.68 ± 6.6851.50 ± 7.230.284Sex, female/male20/524/40.719Height, cm165.20 ± 5.05164.61 ± 7.090.520Weight, kg74.29 ± 8.2372.12 ± 8.000.065Body mass index, kg/m²27.46 ± 2.8426.32 ± 2.370.054Symptom duration, months10.28 ± 6.9012.61 ± 8.260.907Baseline VAS8.24 ± 1.138.14 ± 1.580.861BaselineFFI - R86.28 ± 15.7993.61 ± 19.520.142BaselinePPT23.68 ± 6.1624.57 ± 7.700.646BaselineUSV4.86 ± 0.624.97 ± 0.760.761BMI: body mass index; FFI-R: Foot Function Index–Revised; PPT: pain pressure threshold; USV: ultrasonographic plantar fascia thickness; VAS: Visual Analog Scale.Data are presented as mean ± standard deviation or number of participants. Baseline demographic and clinical characteristics of the participants. BMI: body mass index; FFI-R: Foot Function Index–Revised; PPT: pain pressure threshold; USV: ultrasonographic plantar fascia thickness; VAS: Visual Analog Scale. Data are presented as mean ± standard deviation or number of participants. All 60 randomized participants were included in the intention-to-treat analysis. Four participants had missing outcome data at 6 weeks and seven had missing outcome data at 24 weeks. The proportion of missing follow-up data did not differ significantly between groups at 6 weeks (p = 0.612) or 24 weeks (p = 0.424). At 24 weeks, the baseline-adjusted mean FFI-R score was 49.39 in the plantar-fascia-origin group and 36.35 in the Babcock group. The adjusted between-group mean difference was −13.04 points in favor of the Babcock technique (95% CI, −20.78 to −5.30; p = 0.001). The adjusted 6-week difference was not statistically significant (mean difference, −5.43; 95% CI, −12.13 to 1.27; p = 0.112). The Babcock group demonstrated higher adjusted PPT values at 6 weeks (mean difference, 4.69; 95% CI, 1.84–7.53; p = 0.001) and 24 weeks (mean difference, 7.26; 95% CI, 3.60–10.92; p < 0.001). No statistically significant between-group differences were observed for VAS at 6 or 24 weeks or for ultrasonographic plantar fascia thickness at either follow-up. Within-group analysis demonstrated significant improvements in all outcome measures over time in both treatment groups. Pain intensity (VAS) In the single-point injection group, the mean VAS score decreased significantly from 8.24 ± 1.13 at baseline to 5.60 ± 1.35 at 6 weeks and 3.52 ± 1.81 at 24 weeks (p < 0.001). In the two-point Babcock group, VAS scores also decreased from 8.14 ± 1.58 at baseline to 6.00 ± 1.41 at 6 weeks and 3.21 ± 1.42 at 24 weeks (p < 0.001). Between-group comparisons showed no significant difference in pain intensity at 6 weeks (p = 0.421) or at later follow-ups (Figure S1). Functional outcome (FFI-R) In the single-point group, FFI-R scores improved from 86.28 ± 15.79 at baseline to 68.08 ± 14.34 at 6 weeks and 49.16 ± 14.58 at 24 weeks (p < 0.001). Similarly, in the Babcock group, scores improved from 93.61 ± 19.52 to 65.50 ± 15.49 at 6 weeks and 36.71 ± 9.59 at 24 weeks (p < 0.001) (Table S1). At 24 weeks, the Babcock group demonstrated significantly greater functional improvement compared to the single-point group (p < 0.05) (Figure S2 and Table S1). Pain pressure threshold (PPT) In the single-point group, PPT increased from 23.68 ± 6.16 at baseline to 28.48 ± 6.54 at 6 weeks and 32.12 ± 7.14 at 24 weeks (p < 0.001). In the Babcock group, PPT increased from 24.57 ± 7.70 to 33.89 ± 5.20 at 6 weeks and 40.54 ± 4.80 at 24 weeks (p < 0.001) (Figure S3). Between-group analysis showed significantly higher PPT values in the Babcock group at both 6 weeks (33.89 ± 5.20 vs 28.48 ± 6.54; p = 0.002) and 24 weeks (40.54 ± 4.80 vs 32.12 ± 7.14; p < 0.001), indicating greater improvement in pain tolerance (Table 2). Table 2.Comparison between groups of outcomes at each follow-up time point.VariableSingle-point group (N = 25)Two-point group (N = 28)p valueWeek 6VAS5.60 ± 1.356.00 ± 1.410.421FFI-R68.08 ± 14.3465.50 ± 15.490.344PPT28.48 ± 6.5433.89 ± 5.200.002USV4.50 ± 0.574.45 ± 0.610.727Week 24VAS3.52 ± 1.813.21 ± 1.420.604FFI-R49.16 ± 14.5836.71 ± 9.590.001PPT32.12 ± 7.1440.54 ± 4.80<0.001USV4.34 ± 0.524.17 ± 0.390.359FFI-R: Foot Function Index–Revised; PPT: pain pressure threshold; USV: ultrasonographic plantar fascia thickness; VAS: Visual Analog Scale.Data are presented as mean ± standard deviation. p values represent comparisons between the single-point and two-point injection groups at each follow-up time point. Comparison between groups of outcomes at each follow-up time point. FFI-R: Foot Function Index–Revised; PPT: pain pressure threshold; USV: ultrasonographic plantar fascia thickness; VAS: Visual Analog Scale. Data are presented as mean ± standard deviation. p values represent comparisons between the single-point and two-point injection groups at each follow-up time point. Plantar fascia thickness (USV) In the single-point group, plantar fascia thickness decreased from 4.86 ± 0.62 mm at baseline to 4.50 ± 0.57 mm at 6 weeks and 4.34 ± 0.52 mm at 24 weeks (p < 0.001). In the Babcock group, thickness decreased from 4.97 ± 0.76 mm to 4.45 ± 0.61 mm at 6 weeks and 4.17 ± 0.39 mm at 24 weeks (p < 0.001) (Table S2). No significant differences were observed between the two groups at any time point (p > 0.05) (Figure S4 and Table S2). At 24 weeks, mean VAS scores decreased by 4.72 points in the plantar-fascia-origin group and 4.93 points in the Babcock group. Both improvements exceeded published minimal important difference estimates for average pain and first-step pain in plantar heel pain. Foot Function Index–Revised scores improved by 37.12 and 56.90 points, respectively. These changes were substantially greater than the approximately 6.5-point threshold reported for the original Foot Function Index, although no validated threshold is currently available for the 17-item revised version used in this study. Baseline-adjusted ANCOVA was performed as a complete-case sensitivity analysis among 53 participants. At 6 weeks, the adjusted mean FFI-R score was 70.21 in the plantar-fascia-origin group and 63.60 in the Babcock group, corresponding to an adjusted mean difference of −6.62 points in favor of the Babcock technique (95% CI, −13.04 to −0.19; p = 0.044; partial η2 = 0.079). At 24 weeks, the adjusted mean FFI-R scores were 50.08 and 35.90, respectively, with an adjusted mean difference of −14.18 points (95% CI, −20.70 to −7.66; p < 0.001; partial η2 = 0.276). No significant adjusted between-group differences were observed for VAS at 6 weeks (mean difference, 0.45; 95% CI, −0.23 to 1.13; p = 0.191) or 24 weeks (mean difference, −0.27; 95% CI, −1.13 to 0.59; p = 0.529). In contrast, PPT was significantly higher in the Babcock group at 6 weeks (mean difference, 4.86; 95% CI, 2.65–7.08; p < 0.001; partial η2 = 0.279) and 24 weeks (mean difference, 7.97; 95% CI, 5.23–10.72; p < 0.001; partial η2 = 0.405). The adjusted between-group difference in ultrasonographic plantar fascia thickness was not significant at 6 weeks (−0.118 mm; 95% CI, −0.293 to 0.057; p = 0.183), but a small significant difference favoring the Babcock group was observed at 24 weeks (−0.217 mm; 95% CI, −0.398 to −0.037; p = 0.019; partial η2 = 0.105). Repeated-measures ANOVA was conducted as a complete-case sensitivity analysis among 53 participants with available measurements at baseline, 6 weeks, and 24 weeks. Mauchly’s test indicated that the assumption of sphericity was violated for FFI-R (W = 0.756, p = 0.001), VAS (W = 0.861, p = 0.024), PPT (W = 0.843, p = 0.014), and ultrasonographic plantar fascia thickness (W = 0.769, p = 0.001). Therefore, Greenhouse–Geisser-corrected results were reported. For FFI-R, there was a significant effect of time, F(1.608, 82.012) = 271.37, p < 0.001, partial η2 = 0.842, and a significant Time × Group interaction, F(1.608, 82.012) = 12.00, p < 0.001, partial η2 = 0.191, indicating greater functional improvement over time in the Babcock group. VAS scores also decreased significantly over time, F(1.756, 89.565) = 269.80, p < 0.001, partial η2 = 0.841; however, the Time × Group interaction was not significant, F(1.756, 89.565) = 1.52, p = 0.224, partial η2 = 0.029. PPT increased significantly over time, F(1.728, 88.149) = 150.87, p < 0.001, partial η2 = 0.747, with a significant Time × Group interaction, F(1.728, 88.149) = 14.42, p < 0.001, partial η2 = 0.220, favoring the Babcock technique. Ultrasonographic plantar fascia thickness decreased significantly over time, F(1.625, 82.863) = 71.84, p < 0.001, partial η2 = 0.585, whereas the Time × Group interaction was not significant, F(1.625, 82.863) = 2.99, p = 0.068, partial η2 = 0.055. At 6 weeks, the between-group effect size for FFI-R was small (Cohen’s d = −0.17), whereas a large effect favoring the Babcock technique was observed at 24 weeks (d = −1.02). For PPT, large between-group effects favoring the Babcock technique were observed at both 6 weeks (d = 0.92) and 24 weeks (d = 1.40). The corresponding effect sizes for VAS were small at 6 weeks (d = 0.29) and 24 weeks (d = −0.19). Effect sizes for ultrasonographic plantar fascia thickness were negligible at 6 weeks (d = −0.07) and small at 24 weeks (d = −0.37). Patient satisfaction At 24 weeks, the distribution of satisfaction ratings differed significantly between the groups (p = 0.017). In the plantar-fascia-origin group, 1 participant (4.0%) was very unsatisfied, 4 (16.0%) were unsatisfied, 5 (20.0%) were neutral, 10 (40.0%) were satisfied, and 5 (20.0%) were very satisfied. In the Babcock group, 1 participant (3.6%) was very unsatisfied, 1 (3.6%) was unsatisfied, 6 (21.4%) were neutral, 3 (10.7%) were satisfied, and 17 (60.7%) were very satisfied. Thus, 71.4% of participants in the Babcock group and 60.0% in the plantar-fascia-origin group reported being satisfied or very satisfied.(Figure 5 and Table 3). Distribution of patient satisfaction ratings at 24 weeks in the plantar-fascia-origin and Babcock groups. Satisfaction was assessed using a five-point Likert scale ranging from very unsatisfied to very satisfied. Values are presented as percentages. The distribution of satisfaction ratings differed significantly between groups (p = 0.017). Table 3.Distribution of patient satisfaction levels on a 5-point scale.Level of SatisfactionSingle-Point group (N = 25)Two-point group (N = 28)Very Unsatisfied1 (4.0%)1 (3.6%)Unsatisfied4 (16.0%)1 (3.6%)Neutral5 (20.0%)6 (21.4%)Satisfied10 (40.0%)3 (10.7%)Very Satisfied5 (20.0%)17 (60.7%) Distribution of patient satisfaction levels on a 5-point scale. Both groups improved over time; however, the Babcock technique produced greater improvement in FFI-R and PPT, particularly at 24 weeks. No significant between-group differences were observed for VAS, whereas the ultrasonographic difference was small and inconsistent across analytical approaches. Full adjusted estimates, confidence intervals, effect sizes, and p values are presented in Table 4. In terms of post-injection adverse events, no significant complications were observed in either group, except for mild transient pain at the injection site, which occurred with similar frequency in both groups. Table 4.Baseline-adjusted between-group comparisons of clinical and ultrasonographic outcomes at 6 and 24 weeks in the complete-case sensitivity analysis.OutcomeTimeAdjusted mean: originAdjusted mean: BabcockAdjusted difference95% CIp valuePartial η²FFI-R6 weeks70.2163.60−6.62−13.04 to −0.190.0440.079FFI-R24 weeks50.0835.90−14.18−20.70 to −7.66<0.0010.276VAS6 weeks5.586.020.45−0.23 to 1.130.1910.034VAS24 weeks3.503.23−0.27−1.13 to 0.590.5290.008PPT6 weeks28.7733.634.862.65 to 7.08<0.0010.279PPT24 weeks32.3540.337.975.23 to 10.72<0.0010.405US thickness6 weeks4.5364.418−0.118 mm−0.293 to 0.0570.1830.035US thickness24 weeks4.3694.152−0.217 mm−0.398 to −0.0370.0190.105Values are estimated marginal means obtained from analysis of covariance adjusted for the corresponding baseline outcome. Adjusted differences were calculated as Babcock minus plantar-fascia-origin injection. Negative differences in FFI-R, VAS, and plantar fascia thickness and positive differences in PPT favor the Babcock technique. CI, confidence interval; FFI-R, Foot Function Index–Revised; PPT, pain pressure threshold; VAS, Visual Analog Scale; US, ultrasonographic plantar fascia thickness; η², partial eta squared. Baseline-adjusted between-group comparisons of clinical and ultrasonographic outcomes at 6 and 24 weeks in the complete-case sensitivity analysis. Values are estimated marginal means obtained from analysis of covariance adjusted for the corresponding baseline outcome. Adjusted differences were calculated as Babcock minus plantar-fascia-origin injection. Negative differences in FFI-R, VAS, and plantar fascia thickness and positive differences in PPT favor the Babcock technique. CI, confidence interval; FFI-R, Foot Function Index–Revised; PPT, pain pressure threshold; VAS, Visual Analog Scale; US, ultrasonographic plantar fascia thickness; η², partial eta squared. Discussion Our randomized clinical trial showed that both ultrasound-guided injection techniques produced meaningful improvement over 24 weeks in pain intensity, foot-related function, pressure-pain threshold, and plantar fascia thickness. These findings support the use of botulinum toxin injection as a potential treatment option for patients with chronic plantar fasciitis who remain symptomatic despite conservative management. Importantly, the benefits were not limited to subjective pain relief but were also reflected in functional and mechanical outcomes. The two-point Babcock technique appeared to provide a greater advantage in functional recovery and pressure-pain tolerance, particularly at 24 weeks. The larger improvement in FFI-R and PPT suggests that distributing the injectate across two anatomical sites may produce a broader therapeutic effect than a focal injection at the plantar fascia origin. The higher patient satisfaction observed with the Babcock technique further supports the possibility that these differences were clinically perceptible to participants and not merely statistically detectable. In contrast, the two techniques produced comparable reductions in overall pain intensity and plantar fascia thickness. This indicates that the Babcock method should not be considered universally superior across all outcomes. Rather, its main potential advantage may lie in longer-term functional improvement and reduced mechanical sensitivity, whereas both techniques appear similarly effective for decreasing general pain severity and structural thickening of the plantar fascia. These findings should nevertheless be interpreted cautiously. The modest sample size, single-center design, incomplete monitoring of exercise adherence, and differences between complete-case and intention-to-treat analyses limit the certainty and generalizability of the results. Larger multicenter trials with longer follow-up are needed to determine whether the observed functional benefits are sustained, clinically important, and applicable to broader patient populations. The clinical application of ultrasound-guided plantar fascia injections also requires appropriate technical training. Beginners may experience difficulties with needle–probe alignment, hand–eye coordination, selection of the optimal needle-entry point, maintenance of continuous needle-tip visualization, and handling of longer needles. These challenges may affect injection accuracy and reproducibility, particularly when using different in-plane and out-of-plane approaches. Structured training under expert supervision, together with repeated practice using basic or advanced ultrasound phantoms, may shorten the learning curve and improve procedural confidence and safety. Therefore, clinicians should acquire adequate practical experience in musculoskeletal ultrasonography before independently performing these injection techniques [36]. Patient satisfaction ratings also differed between groups, with a greater proportion of participants in the Babcock group selecting “very satisfied.” However, satisfaction was measured using a single non-validated item and may have been influenced by perceived symptom improvement, treatment expectations, and the injection experience. These findings should therefore be interpreted as supportive and exploratory rather than as definitive evidence of comparative efficacy. Adherence to the post-injection exercise program was assessed only through participant self-report during follow-up and was not quantified using a structured diary or objective monitoring method. Therefore, differences in exercise adherence between participants or treatment groups cannot be completely excluded as a potential influence on the observed outcomes. The magnitude of pain reduction in both groups exceeded available minimal important difference thresholds, suggesting that the observed within-group improvements were clinically meaningful. Functional improvements were also large relative to the threshold reported for the original Foot Function Index; however, this comparison remains indirect because a specific minimal clinically important difference has not been validated for the Foot Function Index–Revised. Clinical importance could not be formally classified for pressure-pain threshold or plantar fascia thickness because established thresholds for these measures are unavailable in plantar fasciitis. These findings are consistent with previous studies reporting the beneficial effects of botulinum toxin in plantar fasciitis. Prior research has demonstrated its role in pain reduction and functional improvement through neuromuscular and analgesic mechanisms. For instance, Díaz-Llopis et al. reported superior and sustained outcomes compared to corticosteroid injections[14]. Similarly, systematic reviews, including Acosta-Olivo et al., have confirmed the effectiveness of botulinum toxin as a therapeutic alternative [37]. Other studies) Li et al. and Lei et al.) evaluating injectable therapies have also shown significant clinical improvement in patients with chronic plantar fasciitis, supporting their role in refractory cases [38,39]. More recent evidence has compared botulinum toxin with regenerative injection therapies. In a randomized trial with one-year follow-up, Ruiz-Hernández et al. found that botulinum toxin produced greater early improvement than platelet-rich plasma, whereas platelet-rich plasma had more favorable longer-term pain and functional outcomes [40]. Both treatments were associated with reductions in plantar fascia thickness, although the timing of structural improvement differed. Together with our results, this indicates that botulinum toxin can produce clinically relevant symptomatic and functional improvement, but its comparative effectiveness depends on the selected outcome and follow-up period. Our study adds to the literature by suggesting that the anatomical distribution of botulinum toxin itself may affect functional and mechanical outcomes; however, this interpretation remains exploratory and requires confirmation in larger trials directly comparing standardized injection techniques. The reason for the greater improvement in FFI-R and PPT observed with the Babcock technique cannot be determined from the present study. One possible explanation is that injection at two anatomical sites may result in a broader distribution of botulinum toxin within the intrinsic plantar musculature and surrounding soft tissues than a single injection at the plantar fascia origin. Such distribution could theoretically influence local muscle tension, mechanical loading of the plantar fascia, or peripheral nociceptive input. However, these mechanisms remain speculative because toxin diffusion and tissue-level effects were not directly measured. The observed differences should therefore not be interpreted as evidence that the Babcock technique produces a specific biomechanical or neurophysiological effect. Other factors, including injection location, local tissue characteristics, technical accuracy, or variation in individual treatment response, may also have contributed. Moreover, the absence of a clear between-group difference in VAS suggests that any potential advantage of the Babcock technique may be more evident in function and localized pressure sensitivity than in overall subjective pain intensity. The improvements observed in both groups should also be interpreted in light of placebo responses and broader contextual effects. Outcomes in musculoskeletal pain are influenced not only by the specific biological action of an intervention but also by treatment expectations, previous experiences, clinician–patient communication, perceived clinician expertise, and the therapeutic ritual of an ultrasound-guided injection [41]. These factors may affect subjective outcomes such as pain ratings and satisfaction. Although both groups received similar clinical attention and participants were blinded to treatment allocation, the injector was not blinded, and subtle differences in communication or procedural delivery cannot be entirely excluded [42]. Because this trial did not include a sham-injection, placebo, or no-treatment group, the observed within-group improvements cannot be attributed solely to botulinum toxin. They may reflect a combination of specific pharmacological effects, contextual influences, natural symptom fluctuation, regression to the mean, and continued exercise. Future trials should therefore consider sham and usual-care comparators and should measure treatment expectations, perceived credibility, and therapeutic alliance to better distinguish specific treatment effects from contextual and nonspecific effects. This study has several limitations. First, seven participants had incomplete follow-up data. Although all 60 randomized participants were retained in the revised intention-to-treat analysis using multiple imputation, the modest amount of missing data and the assumptions underlying imputation may still have influenced the estimates. Complete-case analyses were therefore presented as sensitivity analyses. Second, both study groups received botulinum toxin, and the trial did not include a placebo group, usual-care group, or alternative active treatment such as corticosteroid injection, platelet-rich plasma, or structured exercise alone. Consequently, the study establishes comparative differences between two botulinum toxin injection techniques but cannot determine the magnitude of benefit attributable to botulinum toxin itself or its effectiveness relative to other treatments. Third, although participants and outcome assessors were blinded to treatment allocation, the treating injector could not be blinded because the two procedures involved different anatomical targets. This may have introduced performance bias through subtle differences in procedural technique, communication, or post-procedure management. The use of a standardized injection protocol and identical post-injection instructions was intended to reduce this risk, but it cannot be completely excluded. Finally, participants were recruited from a single center and treated by a limited clinical team. Differences in patient characteristics, clinical expertise, injection technique, rehabilitation practices, and healthcare settings may therefore restrict the external validity of the findings. Larger multicenter trials involving multiple injectors and broader patient populations are needed to confirm the reproducibility and generalizability of these results.Future research should aim to include larger multicenter trials with longer follow-up periods to further evaluate the long-term effectiveness and safety of botulinum toxin injections for plantar fasciitis. Additionally, future studies incorporating electromyography, plantar-pressure analysis, gait assessment, imaging of injectate distribution, or other physiological measures are needed to determine whether the clinical differences observed in this trial are attributable to broader toxin distribution or to another mechanism. Conclusion In conclusion, the findings of our study indicate that both ultrasound-guided botulinum toxin injection techniques were associated with improvements in pain, function, pressure-pain threshold, and plantar fascia thickness over 24 weeks in patients with chronic plantar fasciitis. The two-point Babcock technique showed greater improvement in functional status and pressure-pain threshold and was associated with higher patient satisfaction; however, between-group differences in overall pain intensity were not evident. These findings suggest that the Babcock technique may offer additional benefit for selected functional and mechanical outcomes, but they are insufficient to establish it as the preferred injection approach. Larger multicenter trials with placebo or non-botulinum active comparators and longer follow-up are needed before definitive clinical recommendations can be made. Supplementary Material Supplements.docx CONSORT CHECKLIST.pdf